Oncogenic fusion proteins, arising from chromosomal rearrangements, have emerged as
prominent drivers of tumorigenesis and crucial therapeutic targets in cancer research. In …

Covalent inhibitors have been a rapidly growing field in drug discovery due to their
therapeutic potential and unique advantages in cancer therapy. As opposed to noncovalent …

Objective: BCR ABL oncogene encodes the BCR-ABL chimeric protein, which is a
constitutively activated non-receptor tyrosine kinase. The BCR-ABL oncoprotein is a key …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL
fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation …

Casearlucin A, a diterpenoid obtained from Casearia graveolens, has been reported to
possess strong cytotoxic activity. However, the in vivo anti-tumor effects and the action …

Leukemia is a type of malignant clonal disease of hematopoietic stem cells (HSCs). A small
population of leukemic stem cells (LSCs) are responsible for the initiation, drug resistance …

α-Mangostin, a natural xanthone, was found to have anticancer effects, but these effects are
not sufficient to be effective. To increase anticancer potential and selectivity, a …

Differentiation therapy with all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia
(APL), a subtype of acute myeloid leukemia (AML), has been extremely successful in …

Acute myeloid leukemia (AML) is an aggressive form of hematological neoplasia
characterized by failure of myeloid differentiation. AML is a leading cause of death from …

Acute myelogenous leukemia (AML) is characterized by blockage of cell differentiation
leading to the accumulation of immature cells, which is the most prevalent form of acute …